16 September 2026 editorial review · Trial
MTX228 adaptive phase 2 study in T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Replaced vague eligibility with substantive registry age, diagnosis, treatment and key biomarker restrictions; no efficacy inferred.
Registry: NCT06474598. Endpoint reviewed: Change in AUC C-peptide (Days 0 and 84); Dose selection for phase IIb study (Days 0 and 84). Eligibility reviewed: Age 18 Years to 65 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.